<?xml version='1.0' encoding='utf-8'?>
<document id="25576334"><sentence text="Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature."><entity charOffset="50-61" id="DDI-PubMed.25576334.s1.e0" text="agomelatine" /><entity charOffset="66-90" id="DDI-PubMed.25576334.s1.e1" text="duloxetine hydrochloride" /><pair ddi="false" e1="DDI-PubMed.25576334.s1.e0" e2="DDI-PubMed.25576334.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s1.e0" e2="DDI-PubMed.25576334.s1.e1" /></sentence><sentence text="In this case report, we describe a case in which the clinical pharmacy team was asked to provide recommendations on possible continued use of combination antidepressants in a 62-year-old Slovenian female patient with major depressive disorder following agomelatine and duloxetine hydrochloride-induced excessive sweating"><entity charOffset="253-264" id="DDI-PubMed.25576334.s2.e0" text="agomelatine" /><entity charOffset="269-293" id="DDI-PubMed.25576334.s2.e1" text="duloxetine hydrochloride" /><pair ddi="false" e1="DDI-PubMed.25576334.s2.e0" e2="DDI-PubMed.25576334.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s2.e0" e2="DDI-PubMed.25576334.s2.e1" /></sentence><sentence text=" When agomelatine was administered as an additional treatment, drug-induced excessive sweating was observed after a daily intake of 90 mg of duloxetine hydrochloride and 25 mg of agomelatine"><entity charOffset="6-17" id="DDI-PubMed.25576334.s3.e0" text="agomelatine" /><entity charOffset="141-165" id="DDI-PubMed.25576334.s3.e1" text="duloxetine hydrochloride" /><entity charOffset="179-190" id="DDI-PubMed.25576334.s3.e2" text="agomelatine" /><pair ddi="false" e1="DDI-PubMed.25576334.s3.e0" e2="DDI-PubMed.25576334.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s3.e0" e2="DDI-PubMed.25576334.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25576334.s3.e0" e2="DDI-PubMed.25576334.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25576334.s3.e1" e2="DDI-PubMed.25576334.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25576334.s3.e1" e2="DDI-PubMed.25576334.s3.e2" /></sentence><sentence text=" After thorough discussion, it was decided not to rechallenge with agomelatine because of the serious adverse effect"><entity charOffset="67-78" id="DDI-PubMed.25576334.s4.e0" text="agomelatine" /></sentence><sentence text=" After agomelatine discontinuation and switching to trazodone, symptoms immediately improved"><entity charOffset="7-18" id="DDI-PubMed.25576334.s5.e0" text="agomelatine" /><entity charOffset="52-61" id="DDI-PubMed.25576334.s5.e1" text="trazodone" /><pair ddi="false" e1="DDI-PubMed.25576334.s5.e0" e2="DDI-PubMed.25576334.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s5.e0" e2="DDI-PubMed.25576334.s5.e1" /></sentence><sentence text="" /><sentence text="Duloxetine hydrochloride-induced sweating has been reported frequently, but excessive sweating induced by agomelatine and duloxetine hydrochloride has not been reported in the literature"><entity charOffset="0-24" id="DDI-PubMed.25576334.s7.e0" text="Duloxetine hydrochloride" /><entity charOffset="106-117" id="DDI-PubMed.25576334.s7.e1" text="agomelatine" /><entity charOffset="122-146" id="DDI-PubMed.25576334.s7.e2" text="duloxetine hydrochloride" /><pair ddi="false" e1="DDI-PubMed.25576334.s7.e0" e2="DDI-PubMed.25576334.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s7.e0" e2="DDI-PubMed.25576334.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25576334.s7.e0" e2="DDI-PubMed.25576334.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25576334.s7.e1" e2="DDI-PubMed.25576334.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25576334.s7.e1" e2="DDI-PubMed.25576334.s7.e2" /></sentence><sentence text=" The adverse effect was determined by a clinical pharmacist using the Naranjo probability scale and was probably associated with agomelatine use (6 points) and possibly associated with duloxetine hydrochloride use (4 points)"><entity charOffset="129-140" id="DDI-PubMed.25576334.s8.e0" text="agomelatine" /><entity charOffset="185-209" id="DDI-PubMed.25576334.s8.e1" text="duloxetine hydrochloride" /><pair ddi="false" e1="DDI-PubMed.25576334.s8.e0" e2="DDI-PubMed.25576334.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s8.e0" e2="DDI-PubMed.25576334.s8.e1" /></sentence><sentence text=" The exact mechanism for this adverse effect in this patient is not known, but we believe that a pharmacodynamic drug-drug interaction between agomelatine and duloxetine hydrochloride had occurred"><entity charOffset="143-154" id="DDI-PubMed.25576334.s9.e0" text="agomelatine" /><entity charOffset="159-183" id="DDI-PubMed.25576334.s9.e1" text="duloxetine hydrochloride" /><pair ddi="false" e1="DDI-PubMed.25576334.s9.e0" e2="DDI-PubMed.25576334.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25576334.s9.e0" e2="DDI-PubMed.25576334.s9.e1" /></sentence><sentence text="" /><sentence text="Such a case has not yet been described in literature; however, an adverse effect associated with drug-drug interaction can occur, as this report clearly demonstrates" /><sentence text=" The benefits of this antidepressant combination need to be carefully balanced with the risks associated with its use" /><sentence text=" This case report also highlights the increased potential for adverse reactions when prescribing antidepressant combinations and importance of clinical pharmacists' involvement in the psychiatric patients' pharmacotherapy" /><sentence text="" /></document>